<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501523</url>
  </required_header>
  <id_info>
    <org_study_id>SunYatsenU2H-LQ3</org_study_id>
    <nct_id>NCT04501523</nct_id>
  </id_info>
  <brief_title>A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC</brief_title>
  <acronym>Apollo</acronym>
  <official_title>A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast&#xD;
      cancer, especially triple-negative breast cancer(TNBC). Our trial aims to improve the outcome&#xD;
      of TNBC patients by using ctDNA to identify patients with high relapse risk. ctDNA positive&#xD;
      patients will be randomized to receive boost therapy or standard therapy indicated in NCCN&#xD;
      guidelines after NAC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">August 2032</completion_date>
  <primary_completion_date type="Anticipated">August 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 years Disease free survival(DFS)</measure>
    <time_frame>60 months</time_frame>
    <description>From diagnosis to 5yrs or DFS events; To determine 5-year disease free survival in ctDNA positive participants with confirmed triple negative breast cancer (TNBC) treated with a boost therapy or standard of care following preoperative chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 years overall survival(OS)</measure>
    <time_frame>60 months</time_frame>
    <description>From diagnosis to 5yrs or death; To determine 5-year overall survival in ctDNA positive participants with confirmed triple negative breast cancer (TNBC) treated with a boost therapy or standard of care following preoperative chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete remission(pCR) rate</measure>
    <time_frame>12 months</time_frame>
    <description>pathological complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain metastasis rate</measure>
    <time_frame>60 months</time_frame>
    <description>The percentage of patients who develop brain metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate(ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of patients who achieved PR+CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the toxicities associated with tislelizumab in this population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 years DFS</measure>
    <time_frame>120 months</time_frame>
    <description>To determine 10-year disease free survival in ctDNA positive participants with confirmed triple negative breast cancer (TNBC) treated with a boost therapy or standard of care following preoperative chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 years OS</measure>
    <time_frame>120 months</time_frame>
    <description>To determine 10-year overall survival in ctDNA positive participants with confirmed triple negative breast cancer (TNBC) treated with a boost therapy or standard of care following preoperative chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ctDNA positive, non-pCR Intervention: capecitabine(standard care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ctDNA positive, pCR Intervention: capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow up(standard care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200mg, q3w, for 1 year</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>600-750 mg/m2 PO Bid，continuous, for 1 year</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-)&#xD;
             invasive breast cancer, clinical stage II-III at diagnosis (AJCC 6th edition) based on&#xD;
             initial evaluation by physical examination and/or breast imaging prior to study&#xD;
             registration.ER and PR will be considered negative if ≤ 1% of cells stain weakly&#xD;
             positive. HER2 will be considered negative if scored 0 or 1+ by immunohistochemistry&#xD;
             (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio&#xD;
             of &lt; 2.0 or &lt; 6 copies per cell.&#xD;
&#xD;
          -  Must receive preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable preoperative&#xD;
             regimens include those recommended by NCCN guidelines. Participants who received&#xD;
             preoperative therapy as part of a clinical trial may enroll.&#xD;
&#xD;
          -  ctDNA positive at baseline, after NAC or after surgery&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2&#xD;
&#xD;
          -  Written informed consent to provide research blood samples and tumor samples&#xD;
&#xD;
          -  Patients must be willing to have frequent blood tests (every 3 months ) and receive a&#xD;
             12 month course of tislelizumab if randomised to tislelizumab treatment on ctDNA&#xD;
             detection&#xD;
&#xD;
          -  No evidence of distant metastatic disease on staging scans conducted at the time of&#xD;
             diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously participated in other interventional trials&#xD;
&#xD;
          -  Previous malignancy within 3 years of breast cancer diagnosis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  No written consent&#xD;
&#xD;
          -  Unable to receive standard NAC and subsequent radiotherapy(if needed)&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunyat-sen Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunying Li, MD</last_name>
    <phone>+86-15915939702</phone>
    <email>lishunying@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yudong Li, MD</last_name>
    <phone>020-34071156</phone>
    <email>910870698@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunyat-sen Memorial Hospital</name>
      <address>
        <city>Guandong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shunying Li</last_name>
      <phone>+86-15915939702</phone>
      <email>lishunying@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liu Qiang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

